Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study

scientific article published on 17 February 2010

Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1159/000273461
P698PubMed publication ID20173364

P50authorElisabetta CostantiniQ37829879
Massimo LazzeriQ37829898
P2093author name stringLuigi Mearini
Massimo Porena
Michele Del Zingaro
Vittorio Bini
Antonella Giannantoni
P433issue1
P921main subjectbladder cancerQ504775
P304page(s)23-27
P577publication date2010-02-17
P1433published inUrologia InternationalisQ26854025
P1476titleBacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study
P478volume84

Reverse relations

cites work (P2860)
Q92900076Alternative Therapies to Bacillus Calmette-Guérin Shortage for Nonmuscle Invasive Bladder Cancer in Brazil and Other Underdeveloped Countries: Management Considerations
Q47114392Alternative therapies in patients with non-muscle invasive bladder cancer
Q37970466Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer
Q38943258B7-H4 expression in bladder urothelial carcinoma and immune escape mechanisms
Q87838911Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with non-muscle invasive bladder cancer? An update and cumulative meta-analysis
Q37872240Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy
Q37812604Developments in intravesical therapy for non-muscle-invasive bladder cancer
Q37696178Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis
Q24203884Intravesical gemcitabine for non-muscle invasive bladder cancer
Q37982150Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review
Q37813081Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer.
Q103834991Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure
Q90539551Nonmuscle Invasive Bladder Cancer Influences Physical Health Related Quality of Life and Urinary Incontinence
Q86507875Perioperative chemotherapy: when to use it, what to use, and why
Q84060912Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us?
Q36141505Pityriasis rosea-like rash secondary to intravesical bacillus calmette-guerin immunotherapy
Q42913625Re: Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance
Q39209020Tackling non-muscle invasive bladder cancer in the clinic
Q58795653The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guérin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis
Q54282483[Intravesical gemcitabine for non-muscle invasive bladder cancer].
Q83598879[New concepts in management of NMIBC in 2010]

Search more.